Prof. Yuan-Biao Qiao is a senior leader at the Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on Chronic Inflammation, Shanxi University of Chinese Medicine, China. He holds a BC degree from Taiyuan University of Science and Technology (1992), an MS from Wuhan University (2005), and a Ph.D. from Qingdao University of Science and Technology (2007). Prof. Qiao completed post-doctoral research at Zhejiang University (2008–2010). With over 20 published research articles and a Shanxi Scientific and Technical Award, his work focuses on innovative drug development and integrating traditional Chinese medicine with modern science.
Author Profile
Scopus Profile
🎓EARLY ACADEMIC PURSUITS:
Prof. Yuan-Biao Qiao’s academic journey began with his BC degree from Taiyuan University of Science and Technology in 1992. He furthered his studies at Wuhan University, earning an MS degree in 2005, followed by a Ph.D. from Qingdao University of Science and Technology in 2007. These foundational years highlight his dedication to acquiring a robust academic foundation, enabling him to excel in the field of medicine and traditional Chinese pharmacology.
💼PROFESSIONAL ENDEAVORS:
Prof. Qiao undertook a post-doctoral research stint at Zhejiang University between 2008 and 2010. This critical period allowed him to deepen his expertise, focus on innovative methodologies, and establish a strong presence in the academic and professional communities. Currently, he serves as a senior leader at the Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on Chronic Inflammation, a role that underscores his leadership and research acumen.
Prof. Qiao’s primary research revolves around the development of innovative drugs targeting chronic inflammation and serious diseases, bridging traditional Chinese medicine with modern therapeutic approaches. His publication record includes more than 20 research articles, showcasing his commitment to advancing medical knowledge and addressing pressing healthcare challenges.
🌟IMPACT AND INFLUENCE:
Prof. Qiao’s work has earned him the prestigious Shanxi Scientific and Technical Award, a testament to the significance of his contributions. His research not only advances theoretical understanding but also translates into practical solutions, making a tangible impact on the field of medicine and drug development.
📖ACADEMIC CITES AND COLLABORATIONS:
With a consistent record of publishing high-quality research articles, Prof. Qiao has garnered citations and recognition from peers in the scientific community. His collaborative efforts extend to multidisciplinary teams, reflecting his ability to integrate diverse perspectives and foster innovation in research.
🚀LEGACY AND FUTURE CONTRIBUTIONS:
Prof. Qiao’s ongoing dedication to his field ensures his legacy as a pioneer in integrating traditional Chinese medicine with modern scientific practices. His future endeavors are likely to focus on enhancing the efficacy of therapeutic interventions and contributing to the global recognition of traditional Chinese medicine in treating complex diseases.
🏆CONCLUSION:
Prof. Yuan-Biao Qiao’s extensive academic qualifications, professional expertise, impactful research, and leadership make him a standout candidate for recognition as a Best Researcher. His ability to bridge traditional and modern approaches to medicine exemplifies a legacy of innovation and excellence, ensuring his continued influence in shaping the future of healthcare and science.
TOP NOTABLE PUBLICATIONS
Nrf2/NRF1 signaling activation and crosstalk amplify mitochondrial biogenesis in the treatment of triptolide-induced cardiotoxicity using calycosin
Authors: Qi, X.-M., Zhang, W.-Z., Zuo, Y.-Q., Ren, J.-H., Li, Q.-S.
Journal: Cell Biology and Toxicology
Year: 2025
Herb pair of Huangqi-Danggui exerts anti-tumor immunity to breast cancer by upregulating PIK3R1
Authors: Liu, H.-X., Lian, L., Hou, L.-L., Wen, S.-Y., Li, Q.-S.
Journal: Animal Models and Experimental Medicine
Year: 2024
Methionine redox regulation of actin-interacting proteins primarily governs antioxidative signaling and response to the salvianolic acid B treatment in EA.hy926 cells
Authors: Wang, A.-C., Qi, X.-M., Li, Q.-F., Qiao, Y.-B., Li, Q.-S.
Journal: Toxicology and Applied Pharmacology
Year: 2024
Bidirectional crosstalk of the cAMP/ROS-dependent signaling pathways in inflammatory macrophage: An activation of formononetin
Authors: Zhang, L.-F., Zhang, X.-Y., Wang, A.-C., Qiao, Y.-B., Li, Q.-S.
Journal: Toxicology and Applied Pharmacology
Year: 2023
PGC-1α/NRF1-dependent cardiac mitochondrial biogenesis: A druggable pathway of calycosin against triptolide cardiotoxicity
Authors: Qi, X.-M., Qiao, Y.-B., Zhang, Y.-L., Wei, H.-Z., Li, Q.-S.
Journal: Food and Chemical Toxicology
Year: 2023
Improving endothelial cell junction integrity by diphenylmethanone derivatives at oxidative stress: A dual-action directly targeting caveolar caveolin-1
Authors: Zhang, Y.-L., Yuan, H.-X., Sun, J., Qiao, Y.-B., Li, Q.-S.
Journal: Toxicology and Applied Pharmacology
Year: 2022
GSK3β-dependent lysosome biogenesis: An effective pathway to mitigate renal fibrosis with LM49
Authors: Ren, J., Wei, H., Sun, J., Xiao, B., Li, Q.
Journal: Frontiers in Pharmacology
Year: 2022
The protective effects of Mai-Luo-Ning injection against LPS-induced acute lung injury via the TLR4/NF-κB signalling pathway
Authors: Miao, J., Shen, J., Yan, C., Qiao, Y., Li, Q.
Journal: Phytomedicine
Year: 2022
New taraxasterane-type triterpenes from Diaphragma juglandis Fructus
Authors: Tan, J.-Y., Cheng, Y.-G., Li, J.-L., Li, Q.-S., Wang, Y.-L.
Journal: Tetrahedron Letters
Year: 2022
The Chemical Constituents of Diaphragma Juglandis Fructus and Their Inhibitory Effect on α-Glucosidase Activity
Authors: Tan, J., Cheng, Y., Wang, S., Li, Q., Wang, Y.
Journal: Molecules
Year: 2022